Tissue Repair Ltd (ASX: TRP)
Health Care · Biotechnology · AU
AU$0.09
+2.41% today · -71.7% 1Y
Tissue Repair Ltd (ASX: TRP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.63M and employs 5 people.
Over the last twelve months the share price has lost 71.7%, trading between 0.06 and 0.48.
Tweenvest scores Tissue Repair Ltd across four factors: quality 31/100, value 49/100. Its strongest factor is value.
TRP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.63M
- Revenue (TTM)
- $2.25M
- P/E
- —
- EPS
- -0.06
- Dividend yield
- —
- Beta (5Y)
- 0.22
- 52-week high
- AU$0.48
- 52-week low
- AU$0.06
- Avg volume (3M)
- —
- Shares outstanding
- 60.46M
- Employees
- 5
- Next earnings
- —
About Tissue Repair Ltd
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recovery following cosmetic procedures. Its product pipeline features TR-987 and a suite of innovative dressings and matrices, including the proprietary Glucoprime technology. These are specifically engineered to address challenging conditions such as chronic wounds, burns, and other complex dermal injuries. Additionally, TR Pro+ is being developed for post-procedure care after minimally invasive aesthetic treatments. Beyond these core programs, Tissue Repair is also exploring applications in animal health, novel bandage and scaffold technologies, and various other therapeutic areas. The company was founded in 2012 and operates from its headquarters in Sydney, Australia.
- ISIN
- AU0000180887
- Founded
- 2012
- Listed since
- Nov 17, 2021
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.